Claims for Patent: 4,810,643

Summary for Patent: 4,810,643

Title:	Production of pluripotent granulocyte colony-stimulating factor
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (\"hpG-CSF\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, i.e., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Inventor(s):	Souza; Lawrence M. (Thousand Oaks, CA)
Assignee:	Kirin- Amgen Inc. (Thousand Oaks, CA)
Application Number:	06/835,548
Patent Claims:	1. A purified and isolated DNA molecule for use in securing expression in a procaryotic or eucaryotic host cell of a polypeptide product having at least a part of the primary structural conformation and the hematopoietic biological activity of naturally-occurring pluripotent granulocyte colony-stimulting factor, said DNA selected from among: (a) the DNA molecules set out in FIGS. 2 and 3 or their complementary strands; (b) DNA molecules which hybridize to the DNA molecules defined in (a) or fragments thereof; and (c) DNA molecules which, but for the degeneracy of the genetic code, would hybridize to the DNA molecules defined in (a) and (b). 2. A purified and isolated DNA molecule coding for procaryotic or eucaryotic host expression of a polypeptide product having part or all of the primary structural conformation and the hematopoietic biological activity of human pluripotent granulocyte colony-stimulating factor. 3. A cDNA molecule according to claim 2. 4. A genomic DNA molecule according to claim 3. 5. A maufactured DNA molecule according to claim 2. 6. A manufactured DNA molecule according to claim 5 and including one or more codons preferred for expression in E. coli cells. 7. A manufactured DNA molecule according to claim 5 and including one or more codons preferred for expression in yeast cells. 8. A DNA molecule according to claim 2 covalently associated with a detectable label substance. 9. A DNA molecule according to claim 8 wherein the detectable label is a radiolabel. 10. A single-stranded DNA molecule according to claim 8. 11. A purified and isolated DNA molecule coding for a polypeptide fragment or polypeptide analog of naturally-occurring pluripotent granulocyte colony-stimulating factor and possessing the hematopoietic biological activity thereof. 12. A purified and isolated DNA molecule according to claim 11 coding for [Ala.sup.1 ] hpG-CSF. 13. A biologically functional plasmid or viral DNA vector including a DNA molecule according to one of claims 1, 2 or 11. 14. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to claim 13 in a manner allowing expression of said polypeptide, fragment or analog. 15. A process for the production of a polypeptide product having part or all of the primary structural conformation and the hematopoietic biological activity of naturally occurring pluripotent granulocyte colony-stimulating factor, said process comprising: growing, under suitable nutrient conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA molecule according to claim 1, 2 or 11 in a manner allowing expression of said polypeptide product, and isolating desired polypeptide product of the expression of said DNA molecule. 16. A purified and isolated DNA molecule according to claim 11 coding for [Ser.sup.17 ]hpG-CSF. 17. A polypeptide product of the expression in a procaryotic or eucaryotic host cell of a DNA according to claim 15. 18. A biologically functional plasmid or viral DNA vector including a DNA molecule according to claim 16. 19. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to claim 17. 20. A purified and isolated DNA molecule according to claim 11 coding for an analog of hpG-CSF selected from the group consisting of: [Met.sup.-1 ]hpG-CSF; [Ser.sup.36 ]hpG-CSF; [Ser.sup.42 ]hpG-CSF; [Ser.sup.64 ]hpG-CSF; [Ser.sup.74 ]hpG-CSF; [Met.sup.-1, Ser.sup.17 ]hpG-CSF; [Met.sup.-1, Ser.sup.36 ]hpG-CSF; [Met.sup.-1, Ser.sup.42 ]hpG-CSF; [Met.sup.-1, Ser.sup.64 ]hpG-CSF; and [Met.sup.-1, Ser.sup.74 ]hpG-CSF. 21. A procaryotic or eucaryotic cell transformed or transfected with a DNA molecule according to claim 1 in a manner allowing the host cell to express said polypeptide product. 22. An E. coli host cell according to claim 21. 23. A yeast host cell according to claim 21. 24. A mammalian host host cell according to claim 21. 25. An E. coli host cell according to claim 14. 26. A yeast host cell according to claim 14. 27. A mammalian host cell according to claim 14. 28. A process according to claim 15 wherein said host cells are E. coli cells. 29. A process according to claim 15 wherein said host cells are yeast cells. 30. A process according to claim 15 wherein said host cells are mammalian cells.

Details for Patent 4,810,643

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	February 20, 1991	4,810,643	2006-03-03
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	June 28, 2000	4,810,643	2006-03-03
Amgen Inc.	NEULASTA	pegfilgrastim	Injection	125031	January 31, 2002	4,810,643	2006-03-03
Amgen Inc.	NEULASTA ONPRO	pegfilgrastim	Injection	125031	December 23, 2014	4,810,643	2006-03-03

International Patent Family for US Patent 4,810,643

Country	Patent Number	Estimated Expiration
South Africa	866412
World Intellectual Property Organization (WIPO)	8701132
United States of America	6716606
United States of America	6379661
United States of America	6004548
United States of America	5830705